Alexion posts higher second-quarter earnings on strong Soliris sales

NEW YORK (Reuters) - Alexion Pharmaceuticals Inc posted a better than expected second-quarter profit on Thursday and raised its full-year forecast on strong sales of its expensive rare disease treatment Soliris.